A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the cardiovascular safety of paliperidone in patients
with schizophrenia or schizoaffective disorder, with particular attention to the length of
the QT/QTc interval, to measure and review other electrocardiogram (ECG) parameters, such as
QRS and PR intervals, to explore the relationship between the pharmacokinetics of
paliperidone and ECG parameters of interest, and to explore the safety and tolerability of
paliperidone
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.